IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-Alcoholic Steatohepatitis (NASH)

In brief

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

Key facts

Study ID

NCT05989711

Run by

Altimmune, Inc.

People needed

212

Starts

2023-07-27

Expected to finish

2025-11-25

Last updated by the study team

2026-05-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent
• Male or female 18-75 years
• Histologic diagnosis of NASH and/or histologic confirmation of NASH based on central pathology evaluation of a liver biopsy during screening
• A histologic NAFLD Activity Score (NAS) ≥ 4 with a score of at least 1 on each subcomponent score based on central pathology evaluation (steatosis [0-3], lobular inflammation [0-3], and hepatocyte ballooning [0-2])
• NASH fibrosis stages 2 through 3 according to the NASH CRN fibrosis staging system based on central pathology evaluation
• Subject agrees to have a liver biopsy performed during the screening period (if no biopsy within the preceding 6 months is available) and at 24 weeks of treatment
• BMI ≥ 27.0 kg/m2
• Subjects with Type 2 diabetes mellitus (T2D) should be on a stable treatment regimen for their T2D for at least 90 days prior to screening
• Subject meets at least 3 of the 5 criteria of Metabolic Syndrome (American Heart Association 2005)
• Liver fat content by MRI-PDFF ≥ 8%

You may not qualify if…

• Weight gain or loss > 5% in the 3 months prior to randomization or > 10% in the 6 months prior to screening
• History or clinical evidence of Type 1 diabetes mellitus
• Hemoglobin A1c (HbA1c) > 9.5% or clinically significant persistent hyperglycemia
• Liver conditions:
• History of cirrhosis or complications of cirrhosis, including but not limited to variceal bleeding, encephalopathy, or ascites
• Documented causes of chronic liver disease other than NASH
• ALT or AST laboratory values > 5 × ULN

Where it is running

• Sir Charles Gairdner Hospital — Nedlands, Western Australia, Australia
• Altimmune Clinical Study Site — San Juan, Puerto Rico
• Altimmune Clinical Study Site — Chandler, Arizona, United States
• Altimmune Clinical Study Site — Peoria, Arizona, United States
• Altimmune Clinical Study Site — Tucson, Arizona, United States
• Altimmune Clinial Study Site — Tucson, Arizona, United States
• Altimmune Clinical Study Site — North Hollywood, California, United States
• Altimmune Clinical Study Site — Panorama City, California, United States
• Altimmune Clinical Study Site — Englewood, Colorado, United States
• Altimmune Clinical Study Site — Bradenton, Florida, United States
• Altimmune Clinical Study Site — Fort Myers, Florida, United States
• Altimmune Clinical Study Site — Hialeah Gardens, Florida, United States
• Altimmune Clinical Study Site — Miami Lakes, Florida, United States
• Altimmune Clinical Study Site — Port Orange, Florida, United States
• Altimmune Clinical Study Site — Sarasota, Florida, United States
• Altimmune Clinical Study Site — West Palm Beach, Florida, United States
• Altimmune Clinical Study Site — Dalton, Georgia, United States
• Altimmune Clinical Study Site — Marietta, Georgia, United States
• Altimmune Clinical Study Site — Bastrop, Louisiana, United States
• Altimmune Clinical Study Site — Shreveport, Louisiana, United States
• Altimmune Clinical Study Site — Clarksville, Tennessee, United States
• Altimmune Clinical Study Site — Germantown, Tennessee, United States
• Altimmune Clinical Study Site — Austin, Texas, United States
• Altimmune Clinical Study Site — Bellaire, Texas, United States
• Altimmune Clinical Study Site — Edinburg, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.